首页> Leukemia & lymphoma> Clinical value of molecular MRD monitoring by next-generation sequencing in patients with <i>IDH2</i> mutated AML.

Clinical value of molecular MRD monitoring by next-generation sequencing in patients with <i>IDH2</i> mutated AML.

导出 LinkOut

翻译打印收藏纠错

第一作者： Evgenii,Shumilov

第一单位： Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG) , Göttingen , Germany.

作者： Evgenii,Shumilov ^[1] ; Johanna,Flach ^[2] ; Raphael,Joncourt ^[3] ; Naomi,Porret ^[3] ; Gertrud,Wiedemann ^[3] ; Urban,Novak ^[4] ; Eva,Gfeller ^[5] ; Barbara,Jeker ^[4] ; Ursula,Amstutz ^[6] ; Thomas,Pabst ^[4] ; Ulrike,Bacher ^[5]

作者单位： Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG) , Göttingen , Germany. ^[1] Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University , Mannheim , Germany. ^[2] University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital , Bern , Switzerland. ^[3] Department of Medical Oncology, Inselspital, Bern University Hospital , Bern , Switzerland. ^[4] University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital , Bern , Switzerland.;Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital , Bern , Switzerland. ^[5] Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital , Bern , Switzerland. ^[6]